Agendia receives its 6th FDA clearance with the approval for MammaPrint to be performed on formalin-fixed paraffin embedded (FFPE) tissue.
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome up to 25-years
First ever PROSPECTIVE outcomes study for a breast cancer recurrence assay is published
18-Gene Expression Profile for Colon Cancer Risk of Recurrence released to market
The three assays MammaPrint, BluePrint and TargetPrint are launched as a single “suite of tests”
MammaPrint was selected and incorporated into the Dutch Institute CBO Guidelines for treatment of primary breast cancer
MammaPrint received its first of six FDA clearances
Researchers conclude BluePrint assay may serve as a better guide for physicians’ decisions about how to treat their patients’ early-stage breast cancers before surgery.
The Glück et al., paper showed that BluePrint Molecular Subtyping reclassified up to 25% of breast cancers with better response to neoadjuvant chemotherapy as compared to IHC/FISH assessment
MammaPrint, BluePrint and TargetPrint assays are validated for formalin-fixed, paraffin embedded (FFPE) tissue
BluePrint, 80-Gene Molecular Subtyping Assay is introduced to market
MammaPrint is selected and included in the St. Gallen’s International Oncology Guidelines for treatment of early stage breast cancer
TargetPrint ER/PR?HER2 Expression Assay is launched to market
MammaPrint, 70-Gene Breast Cancer Recurrence Assay is launched as a commercial diagnostic product in Europe
Drs Laura van ‘t Veer and René Bernards publish the landmark discovery paper for MammaPrint in Nature